TOPLINE:
A new, real-world study of around 11,000 multiple myeloma patients across three Nordic countries finds that autologous stem cell transplantation (ASCT) was associated with the longest survival of nearly 8-10 years.
METHODOLOGY:
- This retrospective, population-based study was of all patients with newly diagnosed multiple myeloma (n = 11,023), the second most common haematological malignancy, across Denmark, Finland, and Sweden (2010-2018).
- Data on first-line treatments were obtained from linked national health registries.
- Findings covered patient characteristics, treatment patterns, and overall survival.
TAKEAWAY:
- The median time from diagnosis to treatment was the shortest in Denmark (0.9 months), followed by Sweden (2.9 months) and then Finland (4.6 months).
- The most common treatment was a bortezomib-based regimen (53.5% of patients in Denmark, 50.7% in Finland, and 21.3% in Sweden). The next most common was ASCT, which was received by about one third of patients (36.2% in Denmark, 29.9% in Finland, and 32.5% in Sweden). The least common treatment was melphalan-prednisolone-thalidomide.
- Across the three countries, overall survival from diagnosis to death from any cause was longest for ASCT (93-117 months), followed by a lenalidomide-based regimen (62-78 months), and finally by a bortezomib-based regimen (53-58 months).
IN PRACTICE:
The authors observed that the longest overall survival was seen in patients with ASCT in this “…first large-scale, observational study to describe regional differences in the real-world management of patients with [multiple myeloma] across Nordic countries.”
SOURCE:
The lead and corresponding author was Niels Abildgaard, of Odense University Hospital, Odense, Denmark. The study appeared in the European Journal of Cancer.
LIMITATIONS:
The major study limitation is its retrospective and observational design.
DISCLOSURES:
Eight of the 10 authors reported multiple conflicts of interest. The study received funding from Takeda Pharmaceuticals International AG.
Source link : https://www.medscape.com/s/viewarticle/multiple-myeloma-what-treatments-work-best-real-world-2024a10003kg?src=rss
Author :
Publish date : 2024-02-26 14:00:00
Copyright for syndicated content belongs to the linked Source.